MOTS-c and exercise: the mitokine that mimics physical activity
A plain-English read on a small peptide that rises with exercise and signals metabolic flexibility.
TL;DR
- MOTS-c is a 16-amino-acid peptide encoded inside mitochondrial DNA.
- It rises in human blood after exercise and reproduced several exercise-related effects in mouse studies.
- It is currently a Category 2 peptide and not available from 503A compounding pharmacies.
What it is
MOTS-c (in plain English: mitochondrial open reading frame of the 12S rRNA-c, a 16-amino-acid peptide encoded by a small piece of mitochondrial DNA) is one of a handful of peptides known to come directly from the mitochondria themselves. The category name researchers use is mitokine (in plain English: a hormone-like signal released by mitochondria, the small power plants inside every cell). MOTS-c is the most-studied member of that family (Reynolds et al., Aging Cell, 2018).
How it works
Imagine your mitochondria as power plants that, when stressed by hard work, send a memo to the rest of the body: "We are pushing harder — please help us handle the fuel." MOTS-c is one of those memos. In published rodent research, MOTS-c administration improved how skeletal muscle handles glucose, reduced age-related insulin resistance, and increased physical performance — effects that overlap with what regular exercise produces (Lee et al., Cell Metab, 2015). Human studies have confirmed that MOTS-c levels in blood rise after exercise, particularly after high-intensity work (Reynolds et al., 2018; Yang et al., Sci Rep, 2018).
Who asks about it
People come to this topic after a longevity podcast labels MOTS-c "the exercise peptide" and they want to know if it can replace a workout. The honest answer is no peptide replaces training. The exercise-mimetic label captures a pattern in animal data — not a clinical promise.
What the research says
The original 2015 Cell Metabolism paper showed that MOTS-c administration improved metabolic markers in mice (Lee et al., 2015). A 2018 paper in Aging Cell documented that human MOTS-c levels declined with age and rose acutely after exercise (Reynolds et al., 2018). A 2018 paper in Scientific Reports extended that exercise-response finding (Yang et al., 2018). Human clinical trial data on exogenous MOTS-c administration remains limited compared with the animal literature.
What to know before considering it
MOTS-c is not currently available from licensed compounding channels in the United States. The published evidence base is mostly preclinical and observational. Future clinical use depends on the FDA reclassification process and on the pace of human trials.
The Halftime POV
MOTS-c is the kind of molecule that turns longevity research into a useful conversation. The biology is novel. The exercise-rise pattern is suggestive. The human outcome data is thin. We will not pretend a peptide replaces a workout. We will keep reading.
Related reading:
- MOTS-c: the mitochondria-derived peptide explained
- MOTS-c: the mitochondria-derived peptide in the literature
- MOTS-c and longevity: why a mitochondrial peptide has researchers paying attention
FAQ
Q: What is MOTS-c? A: MOTS-c is a 16-amino-acid peptide encoded inside mitochondrial DNA. It was discovered in 2015 and is studied as a hormone-like signal influencing metabolic flexibility in animal and cell research.
Q: Is MOTS-c an exercise mimetic? A: MOTS-c rises in human blood after exercise in published research, and exogenous MOTS-c reproduced several exercise-related metabolic effects in mouse studies. Researchers describe it as exercise-mimetic — a label that captures the pattern, not a clinical claim.
Q: Is MOTS-c available in 2026? A: MOTS-c is currently classified as a Category 2 peptide and not available from 503A compounding pharmacies. Future access depends on the FDA reclassification pathway.
Disclaimer
As of April 2026, several peptides discussed in this article — including MOTS-c — are classified by the FDA as Category 2, which means they are not currently available from 503A compounding pharmacies. A February 2026 HHS announcement proposed returning these peptides to Category 1 pending formal FDA Federal Register notice. This article is educational and is not medical advice. Halftime Health only prescribes through licensed clinicians in states where our partner physicians are credentialed.
Get updates
Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.
Sources
- Reynolds JC et al., Aging Cell, 2018 — MOTS-c is an exercise-induced mitochondrial-encoded peptide
- Yang Y et al., Scientific Reports, 2018 — Exercise-induced MOTS-c response in human skeletal muscle
This article discusses compounds that are currently under FDA Category 2 review (see our FDA categorization explainer). These compounds are not currently part of Halftime Health's published protocol catalog. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
What is MOTS-c?
MOTS-c is a 16-amino-acid peptide encoded inside mitochondrial DNA. It was discovered in 2015 and is studied as a hormone-like signal influencing metabolic flexibility in animal and cell research.
Is MOTS-c an exercise mimetic?
MOTS-c rises in human blood after exercise in published research, and exogenous MOTS-c reproduced several exercise-related metabolic effects in mouse studies. Researchers describe it as exercise-mimetic — a label that captures the pattern, not a clinical claim.
Is MOTS-c available in 2026?
MOTS-c is currently classified as a Category 2 peptide and not available from 503A compounding pharmacies. Future access depends on the FDA reclassification pathway.
Keep reading
A licensed physician can build a protocol from your own labs.
Membership from $69/mo, including your onboarding panel. Each protocol is its own monthly subscription.